Art Levin

Comanche Biopharma Corp. is a maternal and fetal medicine biopharmaceutical company based in Concord, MA. The company is working to lower the risks of pregnancy and premature births worldwide by developing the world's first treatment for preeclampsia, which affects more than 10 million women every year. Comanche Biopharma's founders have had successful careers discovering new medicines, building and selling companies, and taking on some of the hardest challenges in medicine. Comanche Biopharma is committed to the ethical representation of people of all colors and economic status in their clinical development programs and prioritizes ensuring access to their solutions by those who need them most. The company was founded by Michael Young, and the CEO is T. Scott Johnson.